04:13 AM EST, 01/22/2025 (MT Newswires) -- Evotec (EVO) said Wednesday the company, alongside Yonsei University and biotech firm Zymedi, will receive a $4.5 million grant from the Korea Institute of Advanced Technology to fund the development of therapies to treat lung diseases.

The company said the project will focus on development of new anti-inflammatory and anti-fibrotic antibodies to treat diseases with unmet medical needs, including idiopathic pulmonary fibrosis and non-type 2 asthma.